Lancet study shows long lasting benefit of tamoxifen

A new study in The Lancet shows that five years of tamoxifen improves 15-year survival by about a third in women with hormone-sensitive breast cancer breast cancer.

29 Jul

    • Digg
    • Delicious
    • Google
  • Print it

Dr Caitlin Palframan, Policy Manager at Breakthrough Breast Cancer, said:

“We are really pleased to see such impressive results relating to the long lasting benefits of tamoxifen.  Whilst it’s not suitable for every patient, we are delighted that tamoxifen continues to make such a significant contribution to treating breast cancer.

We are continuing to strive for breakthroughs in new treatments, so that women have even more options available to them.”